Immunohistochemical analyses revealed that CD31 and Ki67 levels were significantly reduced in tumors from mice treated with AAV‐shSH3KBP1 or sorafenib monotherapy, while the combined AAV‐shSH3KBP1 and sorafenib regimen exhibited a more pronounced reduction, indicating a synergistic inhibitory effect on angiogenesis and tumor proliferation via dual‐targeted intervention (Figure 6H). The gene discussed is MKI67; the disease is neoplasm.